Refine by
Crispr Articles & Analysis
36 news found
The emerging Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system has greatly improved the efficiency of genome editing and simplified multilocus genome editing steps. It has also enabled the rapid disruption of metabolic networks. The CRISPR system is an adaptive immune system that allows prokaryotes to defend themselves against the invasion ...
In addition, the company offers CRISPR or siRNA technologies to help clients identify and validate targets of interest by verifying target functional pathways, proliferation, gene expression analysis and protein modification. ...
Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. For example, utilizing CRISPR/Cas9 and other genome-editing tools, scientists are exploring ways to correct mutations that lead to glaucoma. ...
With the development of genetic diagnostics for rare diseases, advances in vector delivery technologies and biotechnologies such as CRISPR-Cas9, gene therapy has become one of the key research directions for therapeutic drugs for rare ...
These chemicals have inclusive applications in mRNA vaccines and therapeutics, RNA therapeutics (ASO, siRNA, miRNA, Aptamer), nucleic acid detection, gene sequencing and editing (CRISPR-Cas9), and oligonucleotide synthesis, etc. It's worth mentioning that BOC Sciences contributed two key nucleosides PseudoUridine and N1-MethylpseudoUridine as the largest manufacturer, which ...
We provide long-read amplicon sequencing of the highest quality and sequence accuracy for applications including full-length 16S, 18S, and ITS rRNA gene sequencing, CRISPR-edited gene characterization, targeted genome resequencing, and other custom amplicon sequencing applications. ...
The third, AAV Transactivation is a CRISPR-Cas–based AAV gene therapy platform that enables to regulate one or multiple genes in vivo. ...
Bringing together Mammoth’s novel CRISPR systems with Bayer’s existing gene augmentation and its induced pluripotent stem cell (iPSC) platforms will allow Bayer to unleash the full potential of its cell and gene therapy strategy. ...
ByBayer AG
“The collaboration pairs AskBio’s expertise in synthetic DNA and CRISPR applications with ReCode’s novel SORT LNP delivery technology to potentially discover new genetic medicines,” said AskBio’s Chief Executive Officer Sheila Mikhail. ...
ByBayer AG
The company is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR system, reduce off-target rates, and further explore genetic information related to human health. ...
Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement Bayer AG and Mammoth Biosciences, Inc., which is ...
“The award serves as a testament to the Mammoth team and the strides we’ve made in building the CRISPR platform that harnesses the potential of this transformative technology across the healthcare spectrum. ...
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. ...
The initial studies, done in collaboration with LIXTE, reveal that the vigorous activation of several oncogenic signaling pathways by LB-100 is associated with marked increases in DNA damage and mitotic stress. CRISPR-based genetic screening and screening of selected investigational compounds both showed that LB-100 is synthetically lethal in combination with inhibitors of the ...
About Caribou’s Novel Next-Generation CRISPR Platform CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. ...
At Mammoth, he will lead the discovery and development of next-generation in vivo gene-editing therapeutics using Mammoth’s ultracompact CRISPR systems. About Mammoth Biosciences Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR ...
This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human gut microbiota based on selective targeting of surface-associated proteins.Importantly, it is one of the few manuscripts listed that is related to microbiome, where most of the others are covid-19 or CRISPR-related. We are thrilled to have ...
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing. The DETECTR BOOST platform is a turnkey, CRISPR-based molecular diagnostic system that enables ...
Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. ...